These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6691684)

  • 1. Neurologic manifestations of essential thrombocythemia.
    Ann Intern Med; 1984 Feb; 100(2):316-7. PubMed ID: 6691684
    [No Abstract]   [Full Text] [Related]  

  • 2. [Inflammatory livedo and idiopathic thrombocythemia. Remarkable therapeutic action of hydroxyurea].
    Lèques B; Texier L; Verdaguer J
    Bull Soc Fr Dermatol Syphiligr; 1967; 74(4):545-8. PubMed ID: 5585217
    [No Abstract]   [Full Text] [Related]  

  • 3. [What should follow a treatment for pruritus in thrombocytosis?].
    Wollina U
    Dtsch Med Wochenschr; 2003 Mar; 128(12):631. PubMed ID: 12649803
    [No Abstract]   [Full Text] [Related]  

  • 4. New approaches to the treatment of thrombocytosis.
    Fruchtman S
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):92-3. PubMed ID: 16224383
    [No Abstract]   [Full Text] [Related]  

  • 5. A case of hydroxyurea-induced transverse melanonychia.
    Teo RY; Tan E
    Int J Dermatol; 2006 Nov; 45(11):1329-30. PubMed ID: 17076717
    [No Abstract]   [Full Text] [Related]  

  • 6. Hydroxyurea in essential thrombocytosis.
    Van Genderen PJ; Michiels JJ
    N Engl J Med; 1995 Sep; 333(12):802-3. PubMed ID: 7643898
    [No Abstract]   [Full Text] [Related]  

  • 7. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.
    Cortelazzo S; Finazzi G; Ruggeri M; Vestri O; Galli M; Rodeghiero F; Barbui T
    N Engl J Med; 1995 Apr; 332(17):1132-6. PubMed ID: 7700286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early cutaneous lesions secondary to hydroxyurea therapy.
    Radaelli F; Calori R; Faccini P; Maiolo AT
    Am J Hematol; 1998 May; 58(1):82-3. PubMed ID: 9590156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critical review of anagrelide therapy in essential thrombocythemia and related disorders.
    Dingli D; Tefferi A
    Leuk Lymphoma; 2005 May; 46(5):641-50. PubMed ID: 16019501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A new etiology of inflammatory livedo: thrombocytosis].
    Lèques B; Texier L; Verdaguer S; Hoffman-Martinot R; Paulet C; Moine M
    Presse Med (1893); 1969 Jan; 77(3):91-2. PubMed ID: 4389318
    [No Abstract]   [Full Text] [Related]  

  • 11. Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis.
    Karanth SS; Gupta A; Prabhu M
    Singapore Med J; 2014 Jan; 55(1):e7-8. PubMed ID: 24452985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity and side effects of hydroxyurea used for primary thrombocythemia.
    Randi ML; Ruzzon E; Tezza F; Luzzatto G; Fabris F
    Platelets; 2005; 16(3-4):181-4. PubMed ID: 16011962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebral venous sinus thrombosis associated with essential thrombocytosis in a pediatric patient.
    Jensen AW; Tefferi A; Arndt CA
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):156-9. PubMed ID: 17356393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.
    Martínez-Trillos A; Gaya A; Maffioli M; Arellano-Rodrigo E; Calvo X; Díaz-Beyá M; Cervantes F
    Ann Hematol; 2010 Dec; 89(12):1233-7. PubMed ID: 20567824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Childhood essential thrombocytosis.
    Papageorgiou T; Theodoridou A; Kourti M; Nikolaidou S; Athanassiadou F; Kaloutsi V
    Pediatr Blood Cancer; 2006 Dec; 47(7):970-1. PubMed ID: 16628554
    [No Abstract]   [Full Text] [Related]  

  • 16. Thrombocytosis.
    Cheung MC; Hicks LK; Pendergrast J
    N Engl J Med; 2004 Jun; 350(24):2524-5; author reply 2524-5. PubMed ID: 15190151
    [No Abstract]   [Full Text] [Related]  

  • 17. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
    Gilbert HS
    Oncology (Williston Park); 2001 Aug; 15(8):989-96, 998; discussion 999-1000,1006,1008. PubMed ID: 11548978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombocythemia and neurologic effects.
    Levin J
    Ann Intern Med; 1984 Jan; 100(1):161-2. PubMed ID: 6691648
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature.
    Internullo M; Giannelli V; Sardo L; Antonaglia C; Villani T; Angelici E; Palange P
    Eur Rev Med Pharmacol Sci; 2014; 18(2):190-3. PubMed ID: 24488907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea-induced leg ulcers: is macroerythrocytosis a pathogenic factor?
    Vélez A; García-Aranda JM; Moreno JC
    J Eur Acad Dermatol Venereol; 1999 May; 12(3):243-4. PubMed ID: 10461646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.